TABLE 1.
Baseline characteristics of the study participants
| Number | 245 |
| Age, years | 61.3 (0.7) |
| Body mass index, kg/m2 | 28.2 (0.3) |
| Hypertension | 153 (64.6) |
| Diabetes mellitus | 56 (23.1) |
| Cardiovascular disease | 198 (81.8) |
| Smoking | 60 (25.3) |
| Statin intolerance | |
| No | 55 (25.6) |
| Partial | 58 (27.0) |
| Complete | 102 (47.4) |
| Lipid lowering therapy | 161 (65.7) |
| Statin | 135 (55.1) |
| Ezetimibe | 123 (50.2) |
| PCSK9, ng/ml | 356 (17) |
| Lipids | |
| Total cholesterol, mmol/l | 6.31 (0.11) |
| LDL-cholesterol, mmol/l | 3.87 (0.10) |
| HDL-cholesterol, mmol/l | 1.19 (0.03) |
| Total triglycerides, mmol/l | 1.98 (0.09) |
| Lathosterol, μmol/l | 13.02 (0.79) |
| Campesterol, μmol/l | 13.89 (0.69) |
| Sitosterol, μmol/l | 16.64 (0.67) |
| Lathosterol:cholesterol, μmol/mmol | 2.00 (0.11) |
| Campesterol:cholesterol, μmol/mmol | 2.21 (0.11) |
| Sitosterol:cholesterol, μmol/mmol | 2.74 (0.12) |
| Campesterol:lathosterol | 2.32 (0.22) |
| Sitosterol:lathosterol | 3.01 (0.27) |
Values are means with standard error in cases of continuous data or numbers and percentages in cases of categorical data; for hypertension, diabetes mellitus, cardiovascular disease, smoking, statin intolerance, and PCSK9, data were available in 237, 242, 242, 237, 215, and 47 patients.